BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans

blonca9
Nov 25, 2024
1 min read

He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put into place, and three key trial readouts to watch over the next year.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

BridgeBio Founder and CEO Neil Kumar discusses the approval of Attruby and the company's commercialization plans

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight